hiranandanihospital.org
Sep 18, 2024, 14:20
Amol Akhade: What’s the story for Day 2 of ESMO2024
Amol Akhade shared a post on X:
“So what’s the story for day 2 of ESMO24 ?
Keynote A18 shows OS benifit.
Pembrolizumab in CTRT for cervix.
HR 0.67 ( 0.5 to 0.90 )
82.6 % vs 74.8 % OS at 36 months.
OS Benifit seen across all the stages.
This should make it new SOC. ”
Source: Amol Akhade/X
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital. He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant. Currently, he is a Consultant Medical Oncologist at Suyog Cancer Clinics and Reliance Hospitals.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14